AnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Recommendation of “Moderate Buy” from Brokerages

AnaptysBio, Inc. (NASDAQ:ANAB) has earned a consensus recommendation of “Moderate Buy” from the twelve analysts that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, two have issued a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $55.40.

A number of equities research analysts have weighed in on the stock. Barclays decreased their target price on shares of AnaptysBio from $70.00 to $55.00 and set an “overweight” rating for the company in a research note on Wednesday. Stifel Nicolaus reduced their price objective on AnaptysBio from $80.00 to $56.00 and set a “buy” rating for the company in a research report on Thursday, December 11th. Truist Financial raised their target price on AnaptysBio from $20.00 to $36.00 and gave the stock a “hold” rating in a research report on Monday, November 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AnaptysBio in a research report on Wednesday, October 8th. Finally, HC Wainwright dropped their price objective on shares of AnaptysBio from $52.00 to $51.00 and set a “buy” rating on the stock in a report on Monday, November 24th.

Insider Activity

In other AnaptysBio news, CFO Dennis Mulroy sold 15,725 shares of the company’s stock in a transaction that occurred on Tuesday, December 16th. The shares were sold at an average price of $44.85, for a total value of $705,266.25. Following the completion of the transaction, the chief financial officer directly owned 9,401 shares in the company, valued at $421,634.85. This represents a 62.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Eric J. Loumeau sold 10,000 shares of the stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $46.00, for a total transaction of $460,000.00. Following the completion of the sale, the insider directly owned 9,088 shares of the company’s stock, valued at approximately $418,048. This trade represents a 52.39% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 38,366 shares of company stock valued at $1,732,642 in the last three months. 33.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On AnaptysBio

Institutional investors have recently bought and sold shares of the business. Larson Financial Group LLC grew its holdings in shares of AnaptysBio by 54.6% in the third quarter. Larson Financial Group LLC now owns 1,340 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 473 shares in the last quarter. Bessemer Group Inc. increased its position in shares of AnaptysBio by 950.0% during the 3rd quarter. Bessemer Group Inc. now owns 1,428 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 1,292 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in AnaptysBio by 175.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,164 shares of the biotechnology company’s stock valued at $48,000 after buying an additional 1,377 shares during the period. Osaic Holdings Inc. lifted its position in AnaptysBio by 11,630.0% in the second quarter. Osaic Holdings Inc. now owns 2,346 shares of the biotechnology company’s stock worth $52,000 after buying an additional 2,326 shares during the last quarter. Finally, Profund Advisors LLC purchased a new position in AnaptysBio during the third quarter worth $201,000.

AnaptysBio Price Performance

Shares of NASDAQ:ANAB opened at $49.08 on Monday. AnaptysBio has a 1 year low of $12.21 and a 1 year high of $49.90. The stock’s fifty day moving average price is $38.80 and its 200-day moving average price is $29.01. The company has a market cap of $1.36 billion, a P/E ratio of -17.40 and a beta of 0.29.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.06) by $1.58. AnaptysBio had a negative net margin of 49.94% and a negative return on equity of 1,101.24%. The firm had revenue of $76.32 million for the quarter, compared to the consensus estimate of $15.83 million. On average, sell-side analysts anticipate that AnaptysBio will post -6.08 earnings per share for the current year.

AnaptysBio declared that its board has authorized a stock buyback plan on Friday, November 21st that authorizes the company to buyback $100.00 million in outstanding shares. This buyback authorization authorizes the biotechnology company to repurchase up to 9.6% of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s board believes its shares are undervalued.

Key Stores Impacting AnaptysBio

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: Guggenheim sharply raised its price target to $140 from $100, signaling strong analyst confidence in AnaptysBio’s pipeline and upside potential—this is a major bullish catalyst that can attract buyers and momentum investors. Guggenheim target raise
• Positive Sentiment: Recent company fundamentals support a stronger valuation: AnaptysBio reported a large revenue beat and positive quarterly EPS last quarter and the board has authorized a $100M buyback (up to ~9.6% of shares), both of which are supportive of higher share prices and institutional interest. MarketBeat company summary
• Neutral Sentiment: Institutional activity is mixed but constructive: some funds increased positions in Q3 while others adjusted exposure—this shows active interest but not a clear one-way flow. Monitor 13F updates for directional confirmation. Institutional holdings
• Negative Sentiment: CFO Dennis Mulroy sold 15,725 shares (~$705k) in mid‑December, reducing his stake by ~62.6%—a large, recent insider sale that can raise investor concern about near‑term insider sentiment. CFO Form 4
• Negative Sentiment: Executive Eric J. Loumeau completed multiple sales (10,000 and other tranches totaling sizable reductions), cutting his position by ~50–60% in filings—additional insider selling increases short‑term downside risk and can sap sentiment. Insider trades alert Loumeau Form 4
• Negative Sentiment: Barclays lowered its price target to $55 from $70 on Dec. 17, which is a modest negative signal that may temper enthusiasm from other bullish research. Barclays target cut

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.